Solid Biosciences (SLDB) Short term Debt (2024 - 2026)

Solid Biosciences has disclosed Short term Debt across 3 years of filings, most recently posting $3.4 million for Q1 2026.

• Short term Debt for Q1 2026 came in at $3.4 million, down 30.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.4 million (down 30.21% YoY), and the FY2025 annual result was $9.2 million, up 192.06% from the prior year.
• Short term Debt came in at $3.4 million for Q1 2026 at Solid Biosciences, down from $9.2 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $9.2 million in Q4 2025 to a low of $3.2 million in Q4 2024.
• The 3-year median for Short term Debt is $4.8 million (2025), against an average of $5.2 million.
• Across the five-year window, Short term Debt surged 192.06% in 2025 and tumbled 30.21% in 2026, its largest moves.
• Solid Biosciences' Short term Debt stood at $3.2 million in 2024, then jumped by 192.06% to $9.2 million in 2025, then tumbled by 63.59% to $3.4 million in 2026.
• The last three Short term Debt figures came in at $3.4 million (Q1 2026), $9.2 million (Q4 2025), and $6.6 million (Q3 2025), per Business Quant data.